Aprea Therapeutics Inc Dossier
Qualitative Analysis
Business overview
Aprea Therapeutics, Inc. is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. The company's core scientific focus is its DNA damage response (DDR) synthetic lethality platform. Its lead clinical-stage pipeline programs include APR-1051, a next-generation, orally bioavailable small-molecule inhibitor of WEE1 kinase, and ATRN-119 (Mosipasertib), an oral small-molecule inhibitor of ataxia telangiectasia and Rad3-related (ATR) kinase. These candidates are designed to exploit genetic mutations in cancer cells to selectively destroy tumors while sparing healthy tissue.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing the next-generation oral WEE1 inhibitor APR-1051 in the ACESOT-1051 Phase 1 trial for patients with advanced solid tumors harboring specific biomarkers (e.g., CCNE1, CCNE2, FBXW7, PPP2R1A mutations).
Expected impact: Aims to demonstrate a differentiated safety and efficacy profile compared to first-generation WEE1 inhibitors.
Shifting focus from monotherapy to evaluating the macrocyclic ATR inhibitor ATRN-119 in combination approaches (e.g., with radiation, immuno-oncology therapies, or antibody-drug conjugates) to maximize therapeutic potential.
Expected impact: Aims to unlock greater clinical benefit and expand the addressable patient population in biomarker-defined cancers.
Expanding the ACESOT-1051 study to enroll at least 50 patients in uterine serous carcinoma (USC) and cyclin E-overexpressing platinum-resistant ovarian cancer (PROC) cohorts.
Expected impact: Refines the biomarker strategy and provides robust proof-of-concept data in specific high-unmet-need populations.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquired to transition Aprea's pipeline toward synthetic lethality and DNA Damage Response (DDR) targets, bringing in the ATR inhibitor ATRN-119 and the WEE1 inhibitor APR-1051.
Financial impact: Shifted the company's R&D focus entirely to the acquired DDR portfolio, which now serves as the core of Aprea's pipeline.
Strategic Partnerships
High. Supports preclinical and early clinical evaluation of WEE1 inhibitor APR-1051 in HPV-positive and HPV-negative head and neck squamous cell carcinoma (HNSCC) expressing genomic markers of replication stress.
Terms: Aprea supplies its proprietary compound APR-1051; MD Anderson conducts preclinical experiments to generate preliminary efficacy and mechanistic data.